Table 5 Subgroup analysis for male
Cardiovascular diseases | Cerebrovascular diseases | Heart dysfunction | Composite outcome | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Patients with outcome | HR (95% CI) | Patients with outcome | HR (95% CI) | Patients with outcome | HR (95% CI) | Patients with outcome | HR (95% CI) | |||||
Non-HPV vaccine | HPV vaccine | Non-HPV vaccine | HPV vaccine | Non-HPV vaccine | HPV vaccine | Non-HPV vaccine | HPV vaccine | |||||
Age | ||||||||||||
20–30 (n = 14,160) | 486 | 503 | 0.946 (0.835, 1.072) | 18 | 45 | 0.392 (0.227, 0.677) | 93 | 79 | 1.157 (0.857, 1.562) | 498 | 539 | 0.904 (0.8, 1.021) |
30–40 (n = 2889) | 113 | 169 | 0.679 (0.535, 0.861) | 10 | 21 | 0.393 (0.174, 0.888) | 23 | 36 | 0.654 (0.387, 1.103) | 117 | 182 | 0.651 (0.516, 0.822) |
Race | ||||||||||||
Black or African American (n = 2244) | 72 | 81 | 0.835 (0.608, 1.146) | 10 | 12 | 0.316 (0.102, 0.978) | 19 | 20 | 0.896 (0.478, 1.68) | 75 | 89 | 0.79 (0.581, 1.074) |
White (n = 9635) | 373 | 347 | 1.068 (0.923, 1.237) | 17 | 34 | 0.497 (0.278, 0.889) | 65 | 58 | 1.112 (0.781, 1.585) | 384 | 370 | 1.031 (0.894, 1.189) |
Asian (n = 1158) | 26 | 28 | 0.934 (0.547, 1.592) | 10* | 10* | 0.198 (0.023, 1.695) | 10* | 10* | 0.677 (0.191, 2.401) | 26 | 33 | 0.789 (0.472, 1.319) |
Other race (n = 990) | 28 | 36 | 0.731 (0.446, 1.197) | 10* | 10* | 0.311 (0.032, 2.987) | 10* | 10* | 0.793 (0.242, 2.6) | 28 | 38 | 0.692 (0.425, 1.128) |